Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China , has announced the signing of an Exclusive Option and License Agreement with Radiance Biopharma Inc., a specialist in antibody drug conjugates (ADCs) headquartered in Boston, U.S.
The agreement provides Radiance with the option to license a pioneering fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) from Biocytogen. The rights granted include global development, manufacturing, and commercialization of the BsADC. According to the terms of the agreement, once Radiance exercises the option, Biocytogen will be entitled to receive an option fee, license fee, development and commercialization milestone payments, as well as single-digit royalties on net sales. Furthermore, Biocytogen retains the right to collect a share of any sublicensing fees that may arise between Radiance and a third party in the future.- Flcube.com
